JP2005527592A - α−ケトアルカン酸または−エステルもしくは−アミドを用いる腸閉塞の処置方法 - Google Patents

α−ケトアルカン酸または−エステルもしくは−アミドを用いる腸閉塞の処置方法 Download PDF

Info

Publication number
JP2005527592A
JP2005527592A JP2003585708A JP2003585708A JP2005527592A JP 2005527592 A JP2005527592 A JP 2005527592A JP 2003585708 A JP2003585708 A JP 2003585708A JP 2003585708 A JP2003585708 A JP 2003585708A JP 2005527592 A JP2005527592 A JP 2005527592A
Authority
JP
Japan
Prior art keywords
ester
ketoalkanoic acid
acid
ketoalkanoic
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003585708A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005527592A5 (enExample
Inventor
フィンク，ミッチェル，ピー．
Original Assignee
クリティカル セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クリティカル セラピューティクス，インコーポレイテッド filed Critical クリティカル セラピューティクス，インコーポレイテッド
Publication of JP2005527592A publication Critical patent/JP2005527592A/ja
Publication of JP2005527592A5 publication Critical patent/JP2005527592A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003585708A 2002-04-17 2003-04-17 α−ケトアルカン酸または−エステルもしくは−アミドを用いる腸閉塞の処置方法 Pending JP2005527592A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37368002P 2002-04-17 2002-04-17
PCT/US2003/012135 WO2003088956A1 (en) 2002-04-17 2003-04-17 Method for treating ileus with an alpha -ketoalkanoic acid or - ester or - amide

Publications (2)

Publication Number Publication Date
JP2005527592A true JP2005527592A (ja) 2005-09-15
JP2005527592A5 JP2005527592A5 (enExample) 2006-05-18

Family

ID=29251059

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003585708A Pending JP2005527592A (ja) 2002-04-17 2003-04-17 α−ケトアルカン酸または−エステルもしくは−アミドを用いる腸閉塞の処置方法
JP2003585707A Pending JP2005526832A (ja) 2002-04-17 2003-04-17 α−ケトアルカン酸エステルまたは−アミドおよび乳酸または乳酸塩を含有する医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2003585707A Pending JP2005526832A (ja) 2002-04-17 2003-04-17 α−ケトアルカン酸エステルまたは−アミドおよび乳酸または乳酸塩を含有する医薬組成物

Country Status (8)

Country Link
US (2) US20030216470A1 (enExample)
EP (2) EP1494659B1 (enExample)
JP (2) JP2005527592A (enExample)
AT (1) ATE306257T1 (enExample)
AU (2) AU2003230996A1 (enExample)
CA (2) CA2481753A1 (enExample)
DE (1) DE60301878T2 (enExample)
WO (2) WO2003088955A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009533433A (ja) * 2006-04-12 2009-09-17 アレクサンダー，ランヤ，エル． ピルビン酸アルキルエステルを含む組成物とその使用

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004014140D1 (de) * 2003-06-13 2008-07-10 Univ Pittsburgh Verfahren zur behandlung von alkoholischer hepatitis
US7464564B2 (en) * 2003-09-22 2008-12-16 Dippin' Dots, Inc. Method and apparatus for combining cookie dough and ice cream
US20050106301A1 (en) * 2003-09-24 2005-05-19 Curt Jones Method and apparatus for cryogenically manufacturing ice cream
EP1689431A4 (en) * 2003-10-27 2010-11-17 Univ Pennsylvania CYTOPROTECTIVE EFFECTS OF ETHYL PYRUVATE
US7316122B1 (en) 2004-01-06 2008-01-08 Dippin' Dots, Inc. Tray for producing particulate food products
US20060062877A1 (en) * 2004-09-21 2006-03-23 Curt Jones Method and apparatus for storing food products
US20060093714A1 (en) * 2004-11-01 2006-05-04 Dippin' Dots, Inc. Particulate ice cream dot cake
US20060093719A1 (en) * 2004-11-01 2006-05-04 Dippin' Dots, Inc. Particulate ice cream dot sandwich
WO2006108681A2 (en) 2005-04-15 2006-10-19 Biomac Privatinstitut Für Medizinische Und Zahnmedizinische Forschung, Entwicklung Und Diagnostik Gmbh Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against bacteria
US7332315B2 (en) * 2005-08-17 2008-02-19 Colgate-Palmolive Company Method to remove bisulfite by-products from enzyme compositions
US20070134394A1 (en) * 2005-12-12 2007-06-14 Dippin' Dots, Inc. Method of manufacturing particulate ice cream for storage in conventional freezers
US20070140044A1 (en) * 2005-12-15 2007-06-21 Dippin' Dots, Inc. Combined particulate and traditional ice cream
US20070140043A1 (en) * 2005-12-16 2007-06-21 Stan Jones Method and apparatus of combining food particles and ice cream
US8603513B2 (en) * 2007-06-28 2013-12-10 The Procter & Gamble Company Article comprising calcium for reducing the production of TSST-1
EP2326317A1 (en) * 2008-09-19 2011-06-01 Cytokine Pharmasciences, Inc Guanylhydrazones for treatment of postoperative intestinal inflammation
CN106727320A (zh) * 2017-01-13 2017-05-31 江苏长泰药业有限公司 一种用于修复鼻粘膜、降低过敏反应、抗炎作用的组合物

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984556A (en) * 1973-01-19 1976-10-05 Sandoz, Inc. Alkyl-substituted-tricyclic quinazolinones for lowering blood pressure
US3879537A (en) * 1973-09-04 1975-04-22 Scott Eugene J Van Treatment of ichthyosiform dermatoses
US3988470A (en) * 1974-02-25 1976-10-26 Scott Eugene J Van Treatment of palmar and plant disturbed keratosis
US4021572A (en) * 1975-07-23 1977-05-03 Scott Eugene J Van Prophylactic and therapeutic treatment of acne vulgaris utilizing lactamides and quaternary ammonium lactates
US4645764A (en) * 1981-04-01 1987-02-24 Montefiore Hospital Method for preventing body fat deposition in animals
US4812479A (en) * 1981-04-01 1989-03-14 The Montefiore Hospital Society Of Western Pennsylvania, Inc. Method for preventing body fat deposition in mammals
US4351835A (en) * 1981-04-01 1982-09-28 Montefiore Hospital Method for preventing body fat deposition in mammals
US4548937A (en) * 1981-04-01 1985-10-22 Montefiore Hospital Method for preventing body fat deposition in mammals
US4415576A (en) * 1981-04-01 1983-11-15 Montefiore Hospital Method for preventing body fat deposition in mammals
DE3581407D1 (de) * 1985-09-06 1991-02-21 Nestle Sa Bewahrung lebender gewebe.
WO1987003808A1 (en) * 1985-12-18 1987-07-02 Veech Richard L Fluid therapy with l-lactate and/or pyruvate anions
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
AU618517B2 (en) * 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US6051609A (en) * 1997-09-09 2000-04-18 Tristrata Technology, Inc. Additives enhancing the effect of therapeutic agents
US4988515A (en) * 1988-01-28 1991-01-29 The Regents Of The Univ. Of Calif. Cardioplegic solution
EP0345082A3 (en) * 1988-06-02 1990-04-04 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Enzyme formation suppressing agent
US5147650A (en) * 1988-07-29 1992-09-15 University Of Florida Compositions and methods for achieving improved physiological response to exercise
US4981687A (en) * 1988-07-29 1991-01-01 University Of Florida Compositions and methods for achieving improved physiological response to exercise
US4874790A (en) * 1988-08-15 1989-10-17 Montefiore Hospital Association Of Western Pennsylvania Method for improving the glucose metabolism of an animal having diabetic tendencies
US5066578A (en) * 1989-12-21 1991-11-19 The Regents Of The University Of California Long-term preservation of organs for transplantation
US5075210A (en) * 1989-12-21 1991-12-24 The Regents Of The University Of California Preservation of the heart for transplantation
US5210098A (en) * 1990-09-21 1993-05-11 Regents Of The University Of Minnesota Use of pyruvate to treat acute renal failure
US5134162A (en) * 1990-12-24 1992-07-28 The Montefiore Hospital Association Of Western Pennsylvania Method for lowering high blood cholesterol levels in hyperlipidemic animals and confections as the ingestion medium
US5981606A (en) * 1991-03-01 1999-11-09 Warner-Lambert Company Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same
US5874479A (en) * 1991-03-01 1999-02-23 Warner-Lambert Company Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same
US5658956A (en) * 1991-03-01 1997-08-19 Warner-Lambert Company Bioadhesive-wound healing compositions and methods for preparing and using same
US5648380A (en) * 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
US5658957A (en) * 1991-03-01 1997-08-19 Warner Lambert Company Immunostimulating wound healing compositions and method for preparing and using same
US5674912A (en) * 1991-03-01 1997-10-07 Warner-Lambert Company Sunscreen-wound healing compositions and methods for preparing and using same
US5652274A (en) * 1991-03-01 1997-07-29 Martin; Alain Therapeutic-wound healing compositions and methods for preparing and using same
US5633285A (en) * 1991-03-01 1997-05-27 Warner-Lambert Company Cytoprotective wound healing compositions and methods for preparing and using same
US5863938A (en) * 1991-03-01 1999-01-26 Warner Lambert Company Antibacterial-wound healing compositions and methods for preparing and using same
US5294641A (en) * 1991-11-27 1994-03-15 Montefiore - University Hospital Method for treating a medical patient for cardiac trauma
US5256697A (en) * 1992-04-16 1993-10-26 Abbott Laboratories Method of administering pyruvate and methods of synthesizing pyruvate precursors
US5508308A (en) * 1992-04-16 1996-04-16 Abbott Laboratories Use of pyruvylglycine to treat ischemia/reperfusion injury following myocardial infarction
PT701455E (pt) * 1993-06-04 2001-09-27 Biotime Inc Solucao semelhante a plasma
US5395822A (en) * 1993-09-20 1995-03-07 Izumi; Yukitoshi Use of pyruvate to prevent neuronal degeneration associated with ischemia
US5612374A (en) * 1994-02-14 1997-03-18 Ronald T. Stanko Inhibiting growth of mammary adenocarcinoma
US5536751A (en) * 1994-05-09 1996-07-16 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof
US5480909A (en) * 1994-08-08 1996-01-02 University Of Pittsburgh Medical Center Method for inhibiting generation of free-radicals
US5801198A (en) * 1995-07-13 1998-09-01 University Of Pittsburgh Medical Center Retarding neutrophil infiltration ad morphologic reduction in ischemic bowel tissues
US5798388A (en) * 1996-09-06 1998-08-25 Cellular Sciences, Inc. Method and composition for treating mammalian diseases caused by inflammatory response
US5876916A (en) * 1996-03-18 1999-03-02 Case Western Reserve University Pyruvate compounds and methods for use thereof
US6086789A (en) * 1996-03-18 2000-07-11 Case Western Reserve University Medical uses of pyruvates
US5667962A (en) * 1996-03-18 1997-09-16 Case Western Reserve University Pyruvate thiolester for the prevention of reperfusion injury
US5843024A (en) * 1996-05-17 1998-12-01 Breonics, Inc. Solution and process for resuscitation and preparation of ischemically damaged tissue
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
US6417231B1 (en) * 1996-12-23 2002-07-09 Frank L. Greenway Method and composition for delivering therapeutically effective amounts of pyruvate to a mammal
GB9724813D0 (en) * 1997-11-25 1998-01-21 Univ Nottingham Reducing muscle fatigue
CN1377266A (zh) * 1999-10-07 2002-10-30 安瑟斯生命科学公司 丙酮酸酯组合物和其在缺血和灌流后复苏中的应用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009533433A (ja) * 2006-04-12 2009-09-17 アレクサンダー，ランヤ，エル． ピルビン酸アルキルエステルを含む組成物とその使用

Also Published As

Publication number Publication date
DE60301878T2 (de) 2006-08-10
EP1494659B1 (en) 2005-10-12
CA2481749A1 (en) 2003-10-30
US20030232884A1 (en) 2003-12-18
ATE306257T1 (de) 2005-10-15
CA2481753A1 (en) 2003-10-30
AU2003230996A1 (en) 2003-11-03
WO2003088956A1 (en) 2003-10-30
AU2003228593B2 (en) 2006-07-27
AU2003228593A1 (en) 2003-11-03
WO2003088955A1 (en) 2003-10-30
EP1494659A1 (en) 2005-01-12
EP1496883A1 (en) 2005-01-19
DE60301878D1 (de) 2006-02-23
WO2003088956A8 (en) 2004-04-15
JP2005526832A (ja) 2005-09-08
US20030216470A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
JP2005527592A (ja) α−ケトアルカン酸または−エステルもしくは−アミドを用いる腸閉塞の処置方法
JP2009543761A (ja) レボドパ／カルビドパの長期間２４時間腸内投与
PT786991E (pt) Compostos poliamina para o tratamento de doencas vasculares proliferativas
Yeung et al. Rectal administration of iodide and propylthiouracil in the treatment of thyroid storm
JPWO2003103659A1 (ja) 過活動膀胱治療剤
Rollinson et al. Postanoxic action myoclonus (Lance-Adams syndrome) responding to valproate
ES2891548T3 (es) Composiciones que contienen silicato y métodos de tratamiento
JP5850518B2 (ja) 高分子化環状ニトロキシドラジカル化合物の潰瘍性消化管の炎症の処置剤
JPS6350329B2 (enExample)
JP6595717B2 (ja) 骨関節炎治療のための親水化されたスルファサラジンおよびヒアルロン酸を含む組成物およびその製造方法
CN1511032A (zh) 含有抗肿瘤成分的甲苯磺胺及其用法
ES2268452T3 (es) Agente con efecto destructivo en tumores malignos asi como procedimiento para su produccion.
JP2004536120A (ja) 細胞殺傷活性を有するカルシウム塩
CN106507666A9 (zh) 1，3‑丙二磺酸或其药学上可接受的盐用于治疗肉样瘤病的用途
TW202120074A (zh) 對羥基苯甲醛於治療發炎性腸道疾病的用途
JP2616845B2 (ja) システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
JP2921872B2 (ja) 経粘膜製剤
Elwood Diagnosis and management of canine oesophageal disease and regurgitation
WO2002020005A1 (en) Use of arginine in endoscopy and other medical procedures
RU2212852C2 (ru) Хирургический способ профилактики прогрессирования панкреонекроза
CN116783212A (zh) 用于调节非人哺乳动物中的癌症的组合物和方法
EP2068873B1 (en) Isoniazid mediated healing of wounds and ulcers
RU2432944C2 (ru) Способ профилактики послеоперационного спаечного процесса в брюшной полости
Rahman Effectiveness and side effects associated with Doxycycline as sclerotherapyin pediatric head and neck lymphangiomas
Lichtenberger et al. Exotic companion mammal emergency techniques

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090730

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100114